Moody Aldrich Partners LLC Cytokinetics Inc Transaction History

Moody Aldrich Partners LLC

$538 Million
Q1 2024

A detailed history of Moody Aldrich Partners LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Moody Aldrich Partners LLC holds 72,897 shares of CYTK stock, worth $3.95 Million. This represents 0.95% of its overall portfolio holdings.

Number of Shares

72,897

Previous 29,871 144.04%

Holding current value

$3.95 Million

Previous $2.49 Million 104.97%

% of portfolio

0.95%

Previous 0.48%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$63.75 - $108.06 $2.74 Million - $4.65 Million	43,026 Added 144.04%	72,897 $5.11 Million
Q4 2023 Jan 25, 2024	SELL	$26.88 - $83.49 $1.74 Million - $5.39 Million	-64,577 Reduced 68.37%	29,871 $2.49 Million
Q3 2023 Nov 07, 2023	BUY	$29.46 - $36.61 $152,367 - $189,346	5,172 Added 5.79%	94,448 $2.78 Million
Q2 2023 Jul 28, 2023	SELL	$32.62 - $40.75 $8,807 - $11,002	-270 Reduced 0.3%	89,276 $2.91 Million
Q1 2023 Apr 27, 2023	SELL	$33.36 - $45.71 $109,654 - $150,248	-3,287 Reduced 3.54%	89,546 $3.15 Million

Q4 2022 Jan 23, 2023	SELL	$35.77 - $51.11 $80,732 - $115,355	-2,257 Reduced 2.37%	92,833 $0
Q3 2022 Oct 18, 2022	SELL	$38.54 - $54.52 $1.7 Million - $2.4 Million	-44,086 Reduced 31.68%	95,090 $4.61 Million
Q2 2022 Jul 18, 2022	BUY	$33.93 - $48.92 $1.51 Million - $2.18 Million	44,620 Added 47.19%	139,176 $5.47 Million
Q1 2022 May 10, 2022	BUY	$29.74 - $46.0 $297,608 - $460,322	10,007 Added 11.84%	94,556 $3.48 Million
Q4 2021 Feb 02, 2022	SELL	$34.35 - $46.38 $536,924 - $724,965	-15,631 Reduced 15.6%	84,549 $3.85 Million
Q3 2021 Oct 29, 2021	BUY	$18.54 - $35.74 $1.86 Million - $3.58 Million	100,180 New	100,180 $3.58 Million

Others Institutions Holding CYTK

# of Institutions

459

Shares Held

108M

Call Options Held

7.2M

Put Options Held

6.2M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $5.1B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Moody Aldrich Partners LLC with notifications on news.

Account

Moody Aldrich Partners LLC Cytokinetics Inc Transaction History